tetano
Editor, Senior Moderator
MMWR Morb Mortal Wkly Rep
. 2020 Dec 18;69(50):1922-1924.
doi: 10.15585/mmwr.mm6950e2.
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020
Sara E Oliver, Julia W Gargano, Mona Marin, Megan Wallace, Kathryn G Curran, Mary Chamberland, Nancy McClung, Doug Campos-Outcalt, Rebecca L Morgan, Sarah Mbaeyi, Jos? R Romero, H Keipp Talbot, Grace M Lee, Beth P Bell, Kathleen Dooling
Abstract
On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania), a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,[SUP]†[/SUP] using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.[SUP]?[/SUP] The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.
. 2020 Dec 18;69(50):1922-1924.
doi: 10.15585/mmwr.mm6950e2.
The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine - United States, December 2020
Sara E Oliver, Julia W Gargano, Mona Marin, Megan Wallace, Kathryn G Curran, Mary Chamberland, Nancy McClung, Doug Campos-Outcalt, Rebecca L Morgan, Sarah Mbaeyi, Jos? R Romero, H Keipp Talbot, Grace M Lee, Beth P Bell, Kathleen Dooling
- PMID: 33332292
- DOI: 10.15585/mmwr.mm6950e2
Abstract
On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine (Pfizer, Inc; Philadelphia, Pennsylvania), a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19) (1). Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation* for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework,[SUP]†[/SUP] using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.[SUP]?[/SUP] The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP's interim recommendation for allocating initial supplies of COVID-19 vaccines (2). The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.